文献速递放疗物理与技术消化道肿瘤放疗泌尿生殖与妇科肿瘤放疗

美国0.35特斯拉磁共振引导放射治疗的利用模式与临床采纳——理解向自适应超低分割治疗的转变

Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-11-22

该研究基于2014至2020年美国全部MRIdian系统的匿名管理数据,描述0.35T磁共振引导放射治疗的利用模式。16个中心的17套系统共完成5736个疗程、36389个分次,其中21.1%为自适应分次;70.3%的疗程采用超低分割(1-5次)。胰、肝、前列腺、乳腺和肺是最常治疗的部位,2020年超低分割占比升至84.9%、桌上自适应再计划升至51.0%。

要点

  • 16个中心17套系统共完成5736个疗程,21.1%的分次为自适应分次。
  • 70.3%的疗程采用超低分割(1-5次),2020年升至84.9%。
  • 至少一个自适应分次的疗程占38.5%,超低分割方案中为47.7%。

核心结论

  • 这是首个报告美国MRIdian早期采纳者利用模式的全面的研究。
  • 分次内磁共振图像引导、先进运动管理和自适应放疗的日益采纳,推动了向超低分割方案的实质性转变。
  • 0.35T磁共振引导放疗主要用于治疗腹部和盆腔肿瘤,桌上自适应再计划的使用不断增加,代表了放射治疗的范式转变。

研究设计与样本

  • 提取2014至2020年美国全部MRIdian治疗系统完成治疗的患者的匿名管理数据。
  • 所有MRIdian直线加速器系统和部分钴系统可获得详细治疗信息。
  • 16个中心的17套系统共完成5736个疗程和36389个分次,其中1223个钴系统疗程的分次详情不可获得。

主要发现

  • 5736个疗程中21.1%的分次为自适应分次。
  • 70.3%的疗程采用超低分割(1-5次)。
  • 38.5%的疗程至少使用一个自适应分次,平均每疗程1.7个自适应分次。
  • 超低分割剂量方案中47.7%的疗程使用桌上自适应再计划,平均每疗程1.9个自适应分次。
  • 最常治疗的器官部位为胰腺20.7%、肝脏16.5%、前列腺12.5%、乳腺11.5%、肺9.4%。

关键数值与推荐

  • 治疗疗程数年复合增长率为59.6%。
  • 2020年超低分割使用增至84.9%的疗程。
  • 2020年桌上自适应再计划使用增至51.0%的疗程。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Magnetic resonance-guided radiation therapy (MRgRT) utilization is rapidly expanding worldwide, driven by advanced capabilities including continuous intrafraction visualization, automatic triggered beam delivery, and on-table adaptive replanning (oART). Our objective was to describe patterns of 0.35Tesla(T)-MRgRT (MRIdian) utilization in the United States (US) among early adopters of this novel technology. MATERIALS/METHODS: Anonymized administrative data from all US MRIdian treatment systems were extracted for patients completing treatment from 2014 to 2020. Detailed treatment information was available for all MRIdian linear accelerator (linac) systems and some cobalt systems. RESULTS: Seventeen systems at 16 centers delivered 5736 courses and 36,389 fractions (fraction details unavailable for 1223 cobalt courses), of which 21.1% were adapted. Ultra-hypofractionation (UHfx) (1-5 fractions) was used in 70.3% of all courses. At least one adaptive fraction was used for 38.5% of courses (average 1.7 adapted fractions/course), with higher oART use in UHfx dose schedules (47.7% of courses, average 1.9 adapted fractions per course). The most commonly treated organ sites were pancreas (20.7%), liver (16.5%), prostate (12.5%), breast (11.5%), and lung (9.4%). Temporal trends show a compounded annual growth rate (CAGR) of 59.6% in treatment courses delivered, with a dramatic increase in use of UHfx to 84.9% of courses in 2020 and similar increase in use of oART to 51.0% of courses. CONCLUSIONS: This is the first comprehensive study reporting patterns of utilization among early adopters of MRIdian in the US. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of adaptive radiation therapy has led to a substantial transition to ultra-hypofractionated regimens. 0.35 T-MRgRT has been predominantly used to treat abdominal and pelvic tumors with increasing use of on-table adaptive replanning, which represents a paradigm shift in radiation therapy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chuong MD, Clark MA, Henke LE, et al. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments. Clin Transl Radiat Oncol. 2022. PMID: 36466748. doi:10.1016/j.ctro.2022.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。